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the EPA reregistration data requirements for 2,4-DB and are the subject of this report. A 1-year dog study was also performed and was described in the paper that preceded this one (Charles and Leeming, 1998) .
MATERIALS AND METHODS
Test chemicals and treatments. The test article was obtained from the manufacturer, A. H. Marks and Company Ltd. The 2,4-DB acid was the technical grade with a purity of 97.7%. The test material was admixed in fresh diets weekly, was fed to the appropriate groups, and was available ad libitum. Unused diets were stored refrigerated in covered stainless-steel containers until fed. Dietary levels were maintained at constant part per million concentration (ppm). Commercially available Punna Certified Rodent Chow No.5002 served as the control diet. 2,4-DB acid was added directly to the Purina Chow without any vehicle.
For the rat chronic/oncogenicity study, there were 80-90 rats/sex/group. Of these animals, 50 rats/sex/group were designated as the oncogenicity animals, 20 rats/sex/group were designated as the chronic toxicity animals, and 10 rats/sex/group were designated for a 12-month euthanization. In addition, in the control and top dose groups, an additional 10 rats/sex/group were designated for a 4-week recovery group at 12 months on test. In a 4-week dose range finding study, significant body weight effects were observed at 1000 and 3000 ppm. Therefore, the doses selected for this long-term study were 0, 60, 600, and 1800 ppm. The top dose recovery group was placed on control diet after 12 months on diets containing the 1800 ppm concentration.
For the mouse oncogenicity study, there were 70 mice/sex/group. Of these animals, 50 mice/sex/group were designated as the oncogenicity animals and 20 mice/sex/group were designated for a 12-month euthanization. The doses selected to be administered to all the animals for 78 weeks were based on the results from a 4-week range finding that demonstrated significantly increased liver weights at 1000 and 3000 ppm. The doses selected for the mouse oncogenicity study were 0, 25, 250, and 750 ppm.
The analytical methodology involved extracting feed samples with methanol/ammonium hydroxide, acidifying the extract and determining 2,4-DB concentrations utilizing reverse-phase HPLC with a UV absorbance detector. Homogeneity and stability of the test articles in the diets were verified prior to die initiation of the studies. The test material was shown to be stable in the diet at room temperature for a period of at least 28 days. For both studies, concentration analyses of the dietary formulations for each group were performed once weekly for the first 4 weeks of each study. Beginning with week 5, and for the remainder of die study, a randomly selected dose-group sample was retained (frozen) each week, and every fourth week, all samples were analyzed along with one control sample and every fourth week thereafter until the studies were terminated. These analyses indicated that all diets were homogeneous and the time weighted average of the dose concentration levels was within ±4% of targeted concentrations for the rat study and ±6% of targeted concentrations for die mouse study.
In the rat study, average test material intake for the males during the 104 weeks of the study for the 60, 600, and 1800 ppm dose groups was 2.48, 25.2, and 78.0 mg/kg/day, respectively. For the females, tbe average test material intake for the 60, 600, and 1800 ppm dose groups was 3.23, 33.4, and 110.6 mg/kg/day, respectively.
In the mouse study, average test material intake for the males during the 78 weeks of the study (66 weeks for the high-dose males) for the 25,250, and 750 ppm dose groups was 3.29, 32.2, and 100.4 mg/kg/day, respectively. For the females, the average test material intake for the 25, 250, and 750 ppm dose groups was 4.21, 40.4, and 128.7 mg/kg/day, respectively.
These studies were conducted in accordance with Good Laboratory Practice regulations and applicable toxicology guidelines for pesticide testing available at the time of the conduct of the study (EPA, 1984; MAFF, 1985; EEC, 1987) .
Laboratory animals and care. Male and female Albino rats (Crl: CD1(SD)BR, 4 weeks old) and albino mice (Crl:CD-l(ICR)BR, 5 weeks old) were obtained from Charles River Laboratories (Wilmington, MA). Rats and mice were selected for the studies based on examination by a veterinarian after an acclimation period of at least 12 days for the rats and 16 days for the mice. Animals were assigned at random to the test and control groups. The animals were individually housed in elevated stainless-steel, wire-mesh cages. A 12-h light/dark cycle was maintained in the room, and food and water were available ad libitum.
For both studies, animals were observed for overt toxicity, moribundity, and mortality at least twice daily. Animal weights and food consumption were determined weekly for the first 14 weeks and then every 2 weeks thereafter for rats, and every 4 weeks for mice, until study termination. The rats and mice were given a detailed examination including palpation for masses on a weekly basis. Ophthalmoscopic examinations on all rats were conducted prior to treatment and prior to each scheduled necropsy (weeks 52, 56, and 104).
Clinical pathology. In the 2-year chronic/oncogenicity rat study, clinical chemistry, hematology, and urinalyses were performed before study initiation, on animals in the chronic toxicity phase of each group at 3, 6, 12, and 18 months on test and on all surviving chronic toxicity animals at study termination. Clinical laboratory studies were also done on the 10 rats/sex/group euthanized at the end of the 4-week recovery period (after 13 months on test). For the mouse study, blood smears were obtained from all animals euthanized at 12 months and at study termination. Differential blood counts were read from males in all dose groups and females in the control and high-dose groups. Selected hematology and blood chemistry parameters were also measured in mice at the 12-month euthanizations. Blood samples were collected by orbital sinus venipuncture under anesthesia following an overnight fast. Urine samples were collected from similarly fasted animals (rats only).
Hematology parameters evaluated in the rat study included erythrocyte count, hematocrit, hemoglobin, leukocyte count, leukocyte differential, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, methemoglobin, Heinz bodies, prothrombin time, and platelet count In the mouse study, the hematology parameters evaluated included erythrocyte count, hematocrit, hemoglobin, leukocyte count, mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration.
Serum chemistry parameters investigated in the rat study included alanine aminotransferase (ALT), albumin, aspartate aminotransferase (AST), blood urea nitrogen (BUN), lactate dehydrogenase (LDH), alkaline phosphatase, y-glutamyltransferase, calcium, chloride, creatinine kinase, globulin, glucose, inorganic phosphorus, potassium, sodium, total bilirubin, total cholesterol, total protein, and albumin. In the mouse study, serum chemistry parameters evaluated included BUN, alkaline phosphatase, AST, ALT, -y-glutamyltransferase, total bilirubin, total cholesterol, and sorbitol dehydrogenase. Urinalysis measurements were not made in the mouse study.
Anatomic pathology. All animals surviving to their scheduled necropsy were anesthetized, exsanguinated, and subjected to gross and microscopic examinations. A complete necropsy was performed on all animals, including those that died on test or were euthanized in a moribund condition. The following organs were weighed: adrenals, brain, heart, kidneys, liver, ovaries, testes (with epididymides), and thyroid/parathyroids (rats only). The following tissues from each animal were preserved in 10% phosphate-buffered formalin: adrenals, aorta, bone marrow (femur), brain (cerebrum, cerebellum, and pons), cecum, cervix, esophagus, eyes (fixed in Zenker's solution), heart, kidneys, lacrimal gland, gallbladder (not rats), duodenum, jejunum, ileum, colon, rectum, liver, lung, mammary gland, mesenteric and submandibular lymph nodes, ovaries, pancreas, pituitary, prostate, salivary gland, skeletal muscle (posterior to femur including sciatic nerve), skin, spinal cord (two levels: cervical, midthoracic/lumbar), spleen, stomach (cardiac, fundus, and pylorus), seminal vesicles, testes, epididymides, thymus, thyroid/parathyroids, trachea, urinary bladder, vagina, uterus, and any other tissues with gross lesions. Preserved tissues were embedded in paraffin, sectioned, and stained with hematoxylin and eosin. All tissues from all animals in the control and top-dose groups and all tissues from all animals in the low-and mid-dose groups that died on test or were moribund euthanized were examined. In addition, lungs, liver, kidneys, tumors, and gross lesions from the animals in the low-and mid-dose groups that survived until their scheduled euthanization were also examined.
Statistics. Rats and mice selected for the studies were stratified by weight and randomly assigned to treatment groups using a computerized randomization program. Bartlett's test, performed following randomization, ensured homogeneity of body weight variances and means (Bartlett, 1937) . Body weight changes, total feed consumption, clinical pathology data (except cell morphology findings and routine urinalysis data), and organ weight data of the control group were compared statistically to the data from the same sex and interval of the treated groups using analysis of variance (ANOVA) (Winer, 1971) . If variances of untransformed data were heterogeneous, a series of transformations was performed in an effort to achieve variance homogeneity using Levene's test (Draper and Hunter, 1969; Levene, 1960) . When the series of transformations was not successful in achieving variance homogeneity, analyses were performed on rank-transformed data. Group comparisons were routinely performed using Dunnett's t test at the 5% two-tailed probability level (Dunnett, 1955 (Dunnett, , 1964 .
RESULTS

Rat Chronic/Oncogenicity Study
Salient results in rats are presented in Tables 1-3 . Antemortem observations that showed an increase in the 1800 ppm dose group included soft feces, alopecia, and thinning haircoat (seen mostly in females during the early phases of the study). No treatment-related observations were seen in the lower dose groups. There were no statistically significant differences in survival. Survival was 31, 35, 38, and 53% for males in the 0, 60, 600, and 1800 ppm groups, respectively. In females, survival was 59, 56, 64, and 57%, respectively. There were no treatment-related ophthalmic observations in either sex.
There were no consistent trends in body weights or cumulative body weight gains for males in the 60 and 600 ppm dose groups and females in the 60 ppm group (Table 1) . Males in the 1800 ppm group had lower body weights and body weight gains for all but 1 week of the study (week 98). The differences were statistically significant for all weeks through week 62 and were not as severe during the second half of the study. Females in the 600 ppm dose group weighed, and gained, less throughout the study. The differences were statistically significant throught week 62. Body weights and cumulative body weight gains were statistically significantly lower for the entire study for the 1800 ppm females. During the recovery period, males and females which had previously been given 1800 ppm of 2,4-DB gained more than their respective control groups, although mean body weights remained lower at the end of the 4-week recovery period.
There were no consistent effects on food consumption for males or females in the 60 or 600 ppm groups (Table 1) . Males and females in the 1800 ppm dose group consumed less food during most of the study and the differences were statistically significant for approximately one-third of the study.
Selected hematology and clinical pathology data are presented in Table 2 . In females at 1800 ppm, RBC count, hemoglobin, hematocrit, and platelet count were all lower than the concurrent control levels. Platelet count in males at this dose level were also lower. The changes in the erythrocytes in females were considered to be mild. Clinical chemistry parameters affected by 2,4-DB at doses of 600 and 1800 ppm included: lowered total protein and globulin in both sexes; a higher A/G ratio in males only; and lowered cholesterol levels in both sexes. Clinical chemistry parameters affected by 2,4-DB only at 1800 ppm included lowered albumin in females; lowered total bilirubin in both sexes; higher ALT levels in males only; and higher alkaline phosphatase levels in both sexes. There were no treatment-related effects noted on any of the urinalysis parameters measured.
The only change at 24 months due to the test material was lower body weights in both sexes at 1800 ppm. No changes in macroscopic or microscopic findings were due to treatment with 2,4-DB. Selected absolute organ weights and organ-tobody weight ratios are presented in Table 3 . Statistically significant organ weight changes were usually secondary to the terminal body weight changes observed at 1800 ppm. Specifically, there were no effects noted in thyroid, kidney, liver, or reproductive organ weights. Other statistically significant organ weight changes were incidental and not toxicologically significant. Histopathological observations probably related to the decreased weight gain in the top dose females included decreases in the incidences of mammary masses, mammary adenomas, fibroadenomas, and adenocarcinomas; pelvic mineralization of the kidneys; and basophilic foci of the liver. There was no indication of any increased incidences of neoplasia in any tissue in this study.
Mouse Oncogenicity Study
Selected results from the 18-month oncogenicity study in mice are presented in Table 4 . Survival rates for female mice ingesting 0, 25, 250, and 750 ppm at the end of the study were 75, 68, 76, and 80%, respectively. To guarantee an adequate number of animals available for histopathological evaluations, all remaining males in the 750 ppm dose group were euthanized and necropsied at week 66 due to low survival. Survival rates for males ingesting 0, 25, 250, and 750 ppm were 48, 53, 49, and 39%, respectively.
Clinical observations which were slightly increased in the 750 ppm group included hunched posture (both sexes), paleness of the entire body (males only), and few or no feces (both sexes). No treatment-related clinical observations were noted in the mid-and low-dose groups. There was no increase of tissue masses for any treated group. There were slight increases in the occurrence of cornea mineralization (cataract), lens degeneration, phthisis bulbi, and retinal degeneration for males and females in the 750 ppm group but in all cases they were unilateral lesions. There were no consistent effects on body weight gains for either sex. Food consumption for males in the 750 ppm group were slightly higher during the first 34 weeks of the study. Food consumption in females in all dose groups were slightly higher for most weeks through Week 50. These differences were considered not to be biologically significant based on the randomness in their occurrence and the lack of a dose-response relationship.
Higher relative neutrophil counts and lower relative lymphocyte and eosinophil counts were seen in 750 ppm males. No other effects on the hematology or the clinical chemistry parameters evaluated were noted in either sex at any other treatment level. Heavier kidney weights were observed at the 12-month and terminal euthanizations in males and females receiving 750 ppm; however, there was no histopathological correlate for this effect. No other organ weight effects were evident in either sex at any other treatment level. In all groups, there were a variety of macroscopic observations that are commonly observed in this age and strain of mouse, but all appeared to be unrelated to the treatment.
Histologically, there was an exacerbation of spontaneous amyloidosis in treated male mice that died on test, at the 12-month interim euthanization, and at the terminal euthanization. The no-effect level for amyloidosis in the male mice was 25 ppm. Although the incidence of amyloidosis was higher in treated female groups than in controls, the overall incidence of this change in female mice precluded a determination of relationship to treatment.
The incidence of alveolar/bronchiolar adenomas, with or without carcinoma was higher in males receiving 25 and 250 ppm, but not 750 ppm and in females receiving 250 ppm. No primary lung tumors were observed in control males. This was not considered to be treatment related due to the lack of a dose-response relationship. There was no indication of any increased incidences of neoplasia in any other tissue in this study.
DISCUSSION
Rat Chronic/Oncogenicity Study
The chronic/oncogenicity study in rats characterized the oncogenic and chronic toxicity potential of 2,4-DB over a dose range of 2.48 to 110.6 mg/kg/day (60 to 1800 ppm). This study clearly established a NOEL of 2.48 mg/kg/day (60 ppm, males) and 3.23 mg/kg/day (60 ppm, females), as well as an MTD of 78.0 (1800 ppm, males) and 110.6 mg/kg/day (1800 ppm, females) for chronic effects (body weight gain depression) of 2,4-DB acid in the rat. Hematologic parameters affected by the test material in one or both sexes included RBC count, hemoglobin, hematocrit, and platelet count. The changes involving the erythrocytes were very mild. Platelet counts, although lower than those of the controls, were not low enough to cause clinical or pathological evidence of a bleeding diathesis. The changes in the clinical chemistry variables were generally mild and were not indicative of toxic injury to a specific target tissue or organ system. The changes in total protein, albumin, globulin, A/G ratio, and cholesterol were probably associated with alterations in the animals' food consumption or assimilation. The cause of the consistent, but very mild lowering of total bilirubin is not known. There were no histopathologic changes in the liver to correlate with the slightly higher ALT and alkaline phosphatase levels. Whether these changes indicate occult hepatic toxicity or physiologic adaptations to altered nutritional status is not known.
In rats receiving no test material for a 4-week recovery period following 12 months of treatment, the changes in erythrocytes, total bilirubin, cholesterol, ALT, and alkaline phosphatase appeared reversible, but platelet counts remained statistically lowered in males. Changes in total protein, globulin, and A/G ratio were not reversed.
Statistically significant organ weight changes were usually secondary to the terminal body weight changes. There were no changes in macroscopic or microscopic findings that were directly due to treatment. Lower incidences of some common aging changes in rats of both sexes were secondary to the lower weight gains observed in the rats dosed at 1800 ppm. No oncogenic effect was observed in rats treated with 2,4-DB for 2 years.
As previously stated, 2,4-DB's major metabolite in animals is 2,4-D. The results reported in the chronic/oncogenicity rat study on 2,4-D are in general agreement with the results of this study. In that study, target organs included kidney and liver; a NOEL of 5 mg/kg/day and an MTD of 150 mg/kg/day were demonstrated. There was no indication of an oncogenic response.
Unlike the present study, lesions (most evident in female rats) were also seen in the eye at the top dose of 150 mg 2,4-D/kg/day and in the thyroid at dose levels of 75 and 150 mg/kg/day. These differences between the two studies may be understood as a threshold phenomenon since the top dose in the 2,4-DB was only 110.6 mg/kg/day (0.44 mmol/kg/day; MW It is also important to keep in mind that the present study was performed utilizing a constant concentration (ppm) in the diet versus the 2,4-D study which was performed utilizing variable concentrations in the diet to maintain a constant milligrams per kilogram per day dosing regime. In addition, the time needed for the metabolic conversion of 2,4-DB to 2,4-D may have also resulted in significantly lower concentrations of 2,4-D in the target organs in question.
The data from the current study are also consistent with an earlier rat oncogenicity study performed on 2,4-D acid under non-GLP conditions (Hansen et al, 1971) . In that study, doses as high as 1250 ppm (approximately 60 mg/kg/day) were administered for up to 2 years. Tumors identified were randomly distributed among types normally found in aging rats. The NOEL from this study is also in agreement with the NOEL for 2,4-DB in the dog of 2.15-2.39 (liver and kidney as target organs) (Charles and Leeming, 1998) and the NOEL of 1 mg/kg/day for 2,4-D in the dog .
Mouse Oncogenicity Studies
The oncogenicity study in mice investigated the oncogenic potential of 2,4-DB over a dose range of 3.29 to 128.7 mg/kg/ day (25 to 750 ppm). There was no clear evidence of an oncogenic potential for 2,4-DB acid in mice, even under conditions in which an MTD may have been exceeded (based on survival in males). These results are consistent with the results of a recently conducted oncogenicity study conducted on 2,4-D . In that study, no oncogenic effect was evident at an MTD dose of 125 mg/kg/day in males and 300 mg/kg/day in females. The lack of an oncogenic response for 2,4-D acid in mice was demonstrated in two other studies: a carcinogenic screening study (Innes et al, 1969) in which neonate mice were intubated with 2,4-D acid and at weaning were continued on diets containing 2,4-D for approximately 18 months and a mouse oncogenicity study conducted at a top dose of 45 mg/kg/day (Serota, 1987) .
The total number of primary epithelial lung tumors in the current study was greater in treated males and females when incidences were combined for mice that were euthanized by design and the unscheduled deaths. However, this was not dose related. Also, the incidence of primary epithelial lung tumors in control animals is considered somewhat low for 18-month-old mice of this strain. Homburger et al. (1975) reports an incidence of 24 to 32% in male and female mice respectively that were approximately 22 months of age. In lifetime studies Eaton et al. (1980) found incidences of 33.1 and 12.3% for males and females, respectively. Percy and Jonas (1971) report a combined incidence of 1.1% in males and females which died between 4 and 20 months and 2.6% incidence in lifetime observations. The ratio of males to females with lung tumors in the Percy and Jonas study was approximately 1:2. It is obvious from these reports that the incidence of primary epithelial lung tumors is quite variable in CD1 mice. In the laboratory where the test was conducted, incidence ranges of 2-17 and 0-22% for males and females, respectively were observed in studies contemporary to this one. Consequently, the increased incidence of epithelial lung tumors in treated animals is considered to be due to natural biologic variation and not an effect of 2,4-DB.
The only toxic effects ascribed to ingestion of the 2,4-DB were higher relative neutrophil counts and lower relative lymphocyte and eosinophil counts in 750 ppm males, minor kidney weight effects in both sexes at 750 ppm, an exacerbation of spontaneous amyloidosis, and slight increases in the occurrence of cornea mineralization (cataract), lens degeneration, phthisis bulbi, and retinal degeneration for males and females in the 750 ppm group.
EPA has set residue tolerances at 0.2 ppm (nondetectable levels at the sensitivity of the analytical method) for alfalfa, clover, mint, hay, peanuts, and soybeans. No residue tolerances exist now or are planned for food items consumed directly by people. While all the commodities listed above are fed to various livestock or poultry, various metabolism and magnitude of residue studies report no detectable residues in edible tissues, milk, or eggs from these animals. There are no registered uses for residential or recreational turf and 2,4-DB does not leach out of the soil into groundwater. Therefore, there is no possible oral exposure to infants, children, or adults. While exposures to farm workers are theoretically possible, the standard use of pants, shoes, hats, long sleeve shirts, and gloves keeps such exposure to an absolute minimum.
The findings of these studies indicate 2,4-DB's general lack of toxicity and absence of oncogenicity following chronic dietary exposure in the dog, rat, and mouse. The overall NOEL of 2.48 mg/kg/day for chronic effects established in the rat (2.15-2.39 mg/kg/day in the dog), in combination with the lack of any significant exposure to the population, support the continued use of 2,4-DB.
